Introducing Bispecifics for Extensive-Stage SCLC

EP: 1.Introduction: Risk Factors and Characteristics Defining SCLC

EP: 2.Established Multidisciplinary Therapies for SCLC

EP: 3.Immunotherapies for Extensive-Stage SCLC

Now Viewing

EP: 4.Introducing Bispecifics for Extensive-Stage SCLC

EP: 5.Standard of Care Durvalumab for Limited-Stage SCLC

EP: 6.Additional Immunotherapies on the Horizon for LS-SCLC

EP: 7.Payer and Patient Education Considerations for SCLC

EP: 8.Biomarker Discovery and Exploration for SCLC

EP: 9.Key Takeaways on Recent Advances in SCLC

EP: 10.Therapies Beyond the Front Line for SCLC

EP: 11.Timing and Urgency Considerations in SCLC

Tarlatamab was given accelerated approval in May 2024 for extensive-stage small cell lung cancer (SCLC). How does this therapy work, and what was the important data the led to its approval?

• What are the main adverse events to watch for, and do you manage them?
• Are there any other clinical considerations, such as inpatient or outpatient dosing, when using a bispecific T-cell engager like tarlatamab?
• Where does this therapy fit into your treatment algorithm for patients with SCLC?